2025-02-12 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**0) Introduction:** This report analyzes Johnson & Johnson (JNJ), a multinational healthcare corporation, based on the provided data.  We will assess its performance relative to the S&P 500 (VOO), examine recent price movements and indicators, and analyze financial statements.


**1) Performance vs. S&P 500:**

JNJ's cumulative return is significantly lower than the S&P 500's.

* **JNJ Cumulative Return:** 33.01%
* **VOO (S&P 500) Cumulative Return:** 120.25%
* **Return Difference:** -87.24%  (This indicates JNJ underperformed VOO substantially.)
* **Relative Divergence:** 10.1% (This places the current underperformance at the 10th percentile of historical relative divergence between JNJ and VOO, indicating a relatively low position compared to the historical range).

The provided CAGR (Compound Annual Growth Rate) data shows inconsistent performance over the years, ranging from a high of 34% to a low of -25%.  The alpha values suggest periods of both underperformance and outperformance relative to the market (beta).  Note the consistently low beta, indicating lower sensitivity to market fluctuations than the overall market.


**2) Recent Price Movement:**

* **Closing Price:** $156.13
* **5-day Moving Average:** $154.34
* **20-day Moving Average:** $150.39
* **60-day Moving Average:** $149.04

The price is above all three moving averages, suggesting a short-term upward trend.  The recent price change (+1.23) indicates a slight upward movement.


**3) Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 75.83  (Indicates overbought conditions, suggesting potential for a price correction.)
* **PPO (Price Oscillator):** 0.38 (Positive value suggests bullish momentum, though a high RSI tempers this optimism).
* **Delta_Previous_Relative_Divergence:** +0.8 (Shows a recent increase in relative strength compared to the market, although this is short-term.)
* **Expected Return:** -253.0% (This is a strikingly negative long-term (2+ years) expected return relative to the S&P 500.  This value needs further clarification and justification.)


**4) Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-10-23 | $1.12  | $22.47B        |
| 2024-07-25 | $1.95  | $22.45B        |
| 2024-05-01 | $1.35  | $21.38B        |
| 2024-02-16 | $1.68  | $21.39B        |
| 2023-10-27 | $10.32 | $21.35B        |

EPS shows significant variability. The exceptionally high EPS in Q4 2023 is a major outlier that needs further investigation to understand if it's an anomaly, a one-time event, or indicative of a significant change in the business.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |
| 2023-12-31 | $21.39B   | 68.23%        |
| 2023-09-30 | $21.35B   | 69.06%        |

Revenue is relatively stable.  Profit margins are consistently high, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity     | ROE          |
|---------|------------|---------------|
| 2024-09-30 | $70.16B   | 3.84%         |
| 2024-06-30 | $71.54B   | 6.55%         |
| 2024-03-31 | $70.02B   | 4.65%         |
| 2023-12-31 | $68.77B   | 5.89%         |
| 2023-09-30 | $71.23B   | 36.54%        |

Equity fluctuates, and ROE (Return on Equity) shows considerable variability, with the Q4 2023 value being an extreme outlier which needs further investigation.


**6) Overall Conclusion:**

JNJ has significantly underperformed the S&P 500 over the measured period.  While financial statements show consistent profitability and relatively stable revenue, the volatile EPS and ROE figures, particularly the extreme values in Q4 2023, raise concerns. The high RSI suggests the stock may be overbought.  The significantly negative expected return (-253%) requires further investigation to determine the validity and assumptions behind this prediction. A thorough review of Q4 2023 results and an understanding of the drivers behind the extreme values in EPS and ROE are crucial for a more informed assessment.  Further analysis is needed to reconcile the short-term positive price movement with the overall negative long-term outlook and the concerning fluctuations in key financial metrics.
